［1］ 胡亚美，江载芳.诸福棠实用儿科学［M］，7版，北京：人民卫生出版社，2002： 2184-2185.

[2] 高解春. 21世纪小儿肿瘤研究展望和防治理念［J］. 中国肿瘤， 2001，10(10):5-7.

[3] Nagaraj S, Ziske C, Schmidt-Wolf I G. Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer［J］. Genet Vaccines Ther, 2004,2(1):12 .

[4] Levin D, Constant S, Pasqualini T, et al. Role of dendritic cells in the priming of CD4+ T lymphocytes to peptide antigen in vivo［J］. Immunol, 1993,151(12):6742-6750.

[5] Tuyaerts S, Van Meirvenne S, Bonehill A，et al. Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells［J］. Leukoc Biol, 2007,82(1):93-105.

[6] 李世俊, 张连生, 柴 晔, 等. 树突状细胞与细胞因子诱导的杀伤细胞共培养对多药耐药肿瘤细胞系的杀伤活性［J］.中华肿瘤杂志， 2007,23(10):733-737.

[7] Sheng K C, Pietersz G A, Wright M D, et al. Dendritic cells: activation and maturation—applications for cancer immunotherapy［J］.Curr MedChem， 2005 ,12(15):1783-1800.

[8] Schmidt-Wolf I G, Lefterova P, Mehta B A, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine -induced killer cells［J］. Exp Hematol, 1993,21(13):1673-1679.

[9] Zoll B, Lefterova P, Csipai M, et al. Generation of cytokine-induced killer cells using exogenous interleukin-2,-7 or-12［J］. Cancer Immunol Immunother,1998，47(4):221-226.

[10] Alvarnas J C, Linn Y C, Hope E G, et al. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation［J］. Biol Blood Marrow Transplant, 2001,7(4):216-222.

[11] Mehta B A, Schmidt-Wolf I G, Weissman I L, et al. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells［J］. Blood, 1995,86(9):3493-3499.

[12] Linn Y C, Wang S M, Hui K M. Comparative gene expression profiling of cytokine-induced killer cells in response to acute myloid leukemic and acute lymphoblastic leukemic stimulators using oligonucleotide arrays［J］. Exp Hematol, 2005,33(6):671-681.

[13] CEN Xinan, ZHU Ping, SHI Yongjin, et al. Cytokine-induced killer cells induce apoptosis of K562 cells expressed bcr-abl［J］. Zhong Guo Shi Yan Xue Ye Xue Za Zhi, 2002,10(3):201-204.

[14] Cooper M A, Fehniger T A, Fuchs A, et al. NK cell and DC interactions［J］. Trends Immunol, 2004,25(1):47-52.

[15] Lau A H, Thomson A W. Dendritic cells and immune regulation in the liver［J］. Gut, 2003,52(2):307-314.

[16] 魏绪仓,翟欣辉,韩秀蕊，等.脐血树突细胞对同源CIK细胞生物活性及抗白血病作用影响的研究［J］.中国实验血液学杂志,2010,18(4):946-951.

[17] 张倩倩，李锦毅.DC与CIK抗肿瘤作用的研究进展［J］.中国实用药,2008,3(9):128-129.

[18] 刘 苗,徐佳伟,金润铭.细胞因子诱导的白血病杀伤细胞的体外生物活性［J］.实用儿科临床杂志,2010,25(15):1144-1147.

[19] 刘 苗,金润铭,姜 毅.树突细胞联合细胞因子诱导的杀伤细胞生物学特性和体外杀瘤机制［J］. 实用儿科临床杂志, 2011,26(1):35-38.

[20] 文 钦,张 曦,陈幸华,等.父供女HLA半相合造血干细胞移植后供者DC-CIK细胞输注治疗儿童难治复发性急性髓细胞白血病1例并文献复习［J］.重庆医学，2010，39(14):1852-1853.［21］ LIU Miao, WU Xianyan, JIN Rumming.Biological characteristics and mechanism of killing tumor of cytokine-induced killer cells［J］. Journal of Applied Clinical Pediatrics ， 2009,24(15):1163-1166.

［22］ SUN Yi, CHEN Jian, CAI Peng, et al. Therapy of relapsed or refractory non-Hodgkin's lymphoma by antigen specific dendritic cells-activated lymphocytes［J］. Zhong guo Shi Yan Xue Ye Xue Za Zhi, 2010,18(1):219-223.

［23］ Leemhuis T, Wells S, Scheffold C, et al. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma［J］. Biol Blood Marrow Transplant, 2005,11(3):181-187.

［24］ Su Y, Fan F Y, Yi H, et al, Autologous tumor cell lysate-loaded dendritic cells and cytokine-induced killer cells in combination with autologous hematopoietic stem cell transpla ntation in the treatment of refractory lymphoma［J］. Chin J Blood Transfusion,2009,22(10):802-805.

［25］ WEI Xucang, ZHAI Xinhui, ZHAO Wenli，et al. Research on the biological activity and anti-tumor effect against lymphoma cells of DC-CIK cells［J］. Chinese-German J Clin Oncol, 2008，11(7):666-669.

［26］ 袁利亚,戎吉平,俞 火,等. 骨髓源性树突状细胞增强CIK细胞抗肿瘤活性的研究［J］.实用临床医学,2008,9(12):4-7.

［27］ Kuci S, Rettinger E, Voss B, et al. Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation［J］. Haematologica, 2010,95(9):1579-1586.

［28］ Verneris M R, Arshi A, Edinger M, et al. Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells［J］. Clin Cancer Res, 2005,11(12):4561-4570. 

［29］ 唐 松,李永平,应方微,等. 视网膜母细胞瘤抗原致敏的树突状细胞疫苗抗SO-RB(50)细胞系的实验研究［J］. 中华眼科杂志,2004,40(4):229-233.

［30］ 郭海霞,黎 阳,薛红漫,等. 儿童神经母细胞瘤的临床分析［J］.中华妇幼临床医学杂志(电子版),2010,6(5):315-318.

［31］ Richard E, Robbie B, Michael T, et al . Synergistic Interleukin-18 and Low-Dose Interleukin-2 Promote Regression of Established Murine Neuroblastoma In Vivo ［J］.Pediatric Surgery, 2003,38(3):301-307.